SCHEMBL6285669

SCHEMBL6285669

O=C(Nc1cccc(O)c1)Nc1ncc(Br)s1

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 1/20 0.56
DYRK1B Q9Y463 1/20 0.56
FBP1 P09467 11/20 0.51
CCNE1 P24864 2/20 0.48
CDK2 P24941 2/20 0.48
CDK5 Q00535 2/20 0.48
BAZ1A Q9NRL2 1/20 0.47
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
ALDH1A1 P00352 2/20 0.46
MEN1 O00255 1/20 0.46
LMNA P02545 1/20 0.46
MAPT P10636 1/20 0.46
HTT P42858 1/20 0.46
KMT2A Q03164 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
TP53 P04637 1/20 0.46
MAPK1 P28482 1/20 0.46
CYP1A2 P05177 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6287753 0.85 FBP1 (0.65) FBP1NPC1RAB9AALDH1A1MEN1
SCHEMBL6285829 0.85 FBP1 (0.65) FBP1CCNE1CDK2CDK5NPC1
SCHEMBL4715713 0.84 CDK2 (0.63) FBP1CCNE1CDK2CDK5NPC1
SCHEMBL6287994 0.83 SMN1; SMN2 (0.52) FBP1CCNE1CDK2CDK5NPC1
SCHEMBL6286205 0.82 RAB9A (0.62) DYRK1ANPC1RAB9AALDH1A1MEN1
SCHEMBL6279016 0.82 CNR1 (0.67) DYRK1ADYRK1BCCNE1CDK2CDK5
SCHEMBL6278567 0.81 KMT2A (0.64) BAZ1ANPC1RAB9AALDH1A1MEN1
SCHEMBL6282898 0.81 CDK2 (0.74) DYRK1ADYRK1BCCNE1CDK2CDK5
SCHEMBL6282688 0.81 CCNE1 (0.67) DYRK1ADYRK1BCCNE1CDK2CDK5
SCHEMBL6279150 0.80 TSHR (0.55) FBP1CCNE1CDK2CDK5NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040157827-A1 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents PEVARELLO PAOLO (IT) 2004-08-12 US claimed
US-20030187040-A1 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents PHARMACIA & UPJOHN SPA (IT) 2003-10-02 US claimed
US-6863647-B2 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents PHARMACIA & UPJOHN S.P.A. (IT) 2005-03-08 US disclosed
US-20040157827-A1 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents PEVARELLO PAOLO (IT) 2004-08-12 US disclosed
US-20030187040-A1 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents PHARMACIA & UPJOHN SPA (IT) 2003-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030187040-A1 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents UCK2, ULK3, CDK2 DYRK1A 1907/4885DYRK1B 1988/4885FBP1 2931/4885
US-20040157827-A1 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents UCK2, ULK3, CDK2 DYRK1A 1907/4885DYRK1B 1988/4885FBP1 2931/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.